


5

## CLAIMS

1. A compound of the formula



10

Formula (I)

wherein Ar is selected from the group consisting of aryl, heteroaryl, benzoheteroaryl, pyridone, pyridazinone, and pyrimidone;

15 n is 1-6;

R<sub>1</sub> and R<sub>2</sub> are independently H, alkyl or aralkyl or R<sub>1</sub> and R<sub>2</sub> along with N can form a pyrrolidine, piperadine, piperazine, morpholine, benzopyrrolidine, benzopiperadine or benzopiperazine ring, or R<sub>1</sub> and L<sub>1</sub> or R<sub>1</sub> and one carbon of (CH<sub>2</sub>)<sub>n</sub> can form a 5, 6, or 7 membered ring;

20 R<sub>3</sub> is H, alkyl or aralkyl;

X and Y are independently C or N;

R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> are independently selected from the group consisting of H, alkyl, aralkyl, aryl, heteroaryl, benzoheteroaryl, hydroxyl, halo, haloalkyl, alkoxy, aminocarbonyl and aminosulfonyl or R<sub>5</sub> and R<sub>6</sub> together can form a 5-6 membered aromatic ring or a 5-7 membered aliphatic ring;

25

L<sub>1</sub> is selected from the group consisting of a single bond, O, NR<sub>7</sub>, CO, SO<sub>2</sub>, NR<sub>8</sub>CO, NR<sub>9</sub>SO<sub>2</sub>, NR<sub>10</sub>CONR<sub>11</sub>, NR<sub>12</sub>SO<sub>2</sub>NR<sub>13</sub>, arene, heteroarene, pyridone, pyrimidone and pyridazinone;


L<sub>2</sub> and L<sub>3</sub> are independently selected from the group consisting of a single bond, CH<sub>2</sub>, NR<sub>14</sub>, CO and SO<sub>2</sub>; and

30

R<sub>7</sub>-R<sub>14</sub> are independently selected from the group consisting of H, alkyl, aryl and aralkyl or R<sub>8</sub> and CO and Ar can form pyridone, pyridazinone, and pyrimidone, and the pharmaceutically

5 acceptable salts thereof.

2. A compound of claim 1 of the formula




10

wherein each  $R_{15}$  is independently H, alkyl, aralkyl, haloalkyl, aryl, heteroaryl, benzoheteroaryl, alkoxy, aminocarbonyl or aminosulfonyl and two of  $R_{15}$  can form a 5-6 membered aromatic ring or a 5-7 membered aliphatic ring; m is 0-3; and

15  $R_1$ ,  $R_2$ ,  $R_4$ ,  $R_5$ ,  $R_6$ , n, X and Y are as defined in claim 1, and the pharmaceutically acceptable salts thereof.

3. A compound of claim 1 of the formula:



20

wherein each  $R_{15}$  is independently H, alkyl, aralkyl, haloalkyl, aryl, heteroaryl, benzoheteroaryl, alkoxy, aminocarbonyl or aminosulfonyl and two of  $R_{15}$  can form a 5-6 membered aromatic ring or a 5-7 member aliphatic ring;

25 M is 0-3; and

$R_1$ ,  $R_2$ ,  $R_4$ ,  $R_5$ ,  $R_6$ , n and X are as defined in claim 1, and the pharmaceutically acceptable salts thereof.

- 5 4. A compound of claim 1 selected from the group consisting of:
- {4-Chloro-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- {3-[2-(4-Benzylpiperidin-1-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- {4-Chloro-3-[2-(4-phenylpiperidin-1-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- 10 {3-[2-(4-Benzylpiperazin-1-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- {3-[2-(Benzylmethylamino)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- {3-[2-(4-Benzylpiperidin-1-yl)ethoxy]-5-trifluoromethylphenyl}-(2-methylquinolin-4-yl)amine;
- {3-[3-(4-Benzylpiperidin-1-yl)propoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- 15 {3-[2-(1-Methyl-1-phenylethylamino)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- [3-(2-Benzylaminoethoxy)phenyl}-(2-methylquinolin-4-yl)amine;
- 1-(1-{2-[3-(2-Methylquinolin-4-ylamino)phenoxy]ethyl}-4-phenylpiperidin-4-yl)ethanone;
- [3-(3-Benzylaminopropoxy)phenyl}-(2-methylquinolin-4-yl)amine;
- {3-[2-(2-Benzylimidazol-1-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- 20 (1-{2-[3-(2-Methylquinolin-4-ylamino)phenoxy]ethyl}piperidin-4-yl)diphenylmethanol;
- 4-Benzyl-1-{2-[3-(2-tert-butylquinolin-4-ylamino)phenoxy]ethyl}piperidin-4-ol;
- 4-Benzyl-1-{2-[3-(2-methylquinolin-4-ylamino)-5-trifluoromethylphenoxy]ethyl}piperidin-4-ol;
- {3-[2-(4-Benzylpiperidin-1-yl)ethoxy]phenyl}-(2,6-dimethylpyrimidin-4-yl)amine;
- 25 {3-[2-(5-Benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- {3-[2-(4-Benzylpiperazin-1-yl)ethoxy]-5-trifluoromethylphenyl}-(2-methylquinolin-4-yl)amine;
- (2-Methylquinolin-4-yl)-{3-[2-(4-phenylpiperidin-1-yl)ethoxy]-5-trifluoromethyl
- 30 phenyl}amine;
- {3-[3-(1-Methyl-1-phenylethylamino)propoxy]phenyl}-(2-methylquinolin-4-yl)amine.
- {3-[2-(5-Benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)ethoxy]-5-trifluoromethylphenyl}-(2-methylquinolin-4-yl)amine;
- N-(2-{1-[2-(3-Fluorophenyl)ethyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl}ethyl)-3-

5 (2-methylquinolin-4-ylamino)benzamide;  
 N-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-3-(2-methylquinolin-4-ylamino)benzamide;  
 N-[2-(1,3-Dihydroisoindol-2-yl)ethyl]-3-(2-methylquinolin-4-ylamino)benzamide;  
 N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-2-methyl-5-(2-methylquinolin-4-ylamino)benzamide;  
 10 N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-2-hydroxy-5-(2-methylquinolin-4-ylamino)benzamide;  
 N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-3-(2-trifluoromethylquinolin-4-ylamino)benzamide;  
 15 N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-2,4,6-trimethyl-3-(2-methylquinolin-4-ylamino)benzamide;  
 2-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-4-(2-methylquinolin-4-ylamino)-2,3-dihydroisoindol-1-one;  
 3-(2-Methylquinolin-4-ylamino)-N-[2-(1,3,4,5-tetrahydrobenzo[c]azepin-2-yl)ethyl]benzamide;  
 20 N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-2,5-bis(2-methylquinolin-4-ylamino)benzamide;  
 3-(2-Methylquinolin-4-ylamino)-N-[2-(octahydro-cis-isoquinolin-2-yl)ethyl]benzamide;  
 N-(2-Azepan-1-ylethyl)-3-(2-methylquinolin-4-ylamino)benzamide;  
 25 N-(2-Benzylaminoethyl)-3-(2-methylquinolin-4-ylamino)benzamide;  
 4-({2-[3-(2-Methylquinolin-4-ylamino)-benzoylamino]ethylamino}methyl)benzoic acid;  
 N-[2-(2,2-Dimethylpropylamino)ethyl]-3-(2-methylquinolin-4-ylamino)benzamide;  
 N-[2-(4-Benzylpiperazin-1-yl)ethyl]-3-(2-methylquinolin-4-ylamino)benzenesulfonamide;  
 {3-[5-(3,4-Dihydro-1H-isoquinolin-2-ylmethyl)isoxazol-3-yl]phenyl}-(2-methylquinolin-4-yl)amine;  
 30 {3-[3-(3,4-Dihydro-1H-isoquinolin-2-yl)propyl]-4-methylphenyl}-(2-methylquinolin-4-yl)amine;  
 N<sup>1</sup>-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-N<sup>7</sup>-(2-methylquinolin-4-yl)-1,2,3,4-tetrahydronaphthalene-1,7-diamine;

5 [3'-(3,4-Dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-yl]-(2-methylquinolin-4-yl)amine;  
 {3-[2-(4-Benzylpiperidin-1-yl)ethanesulfonyl]phenyl}-(2-methylquinolin-4-yl)amine;  
 N-[2-(4-Benzylpiperidin-1-yl)ethyl]-N'-(2-methylquinolin-4-yl)pyrimidine-4,6-diamine; and  
 3-(4-Benzylpiperidin-1-yl)-1-[3-(2-methylquinolin-4-ylamino)phenyl]propan-1-one oxime;

10 5. A pharmaceutical composition comprising a compound of claim 1 and a  
 pharmaceutically acceptable carrier or excipient.

6. A method of treating conditions associated with urotensin-II imbalance by  
 antagonizing the urotensin-II receptor which comprises administering to a patient in need  
 15 thereof, a compound of claim 1.

7. A method according to claim 6 wherein the condition is selected from the group  
 consisting of congestive heart failure, stroke, ischemic heart disease, angina, myocardial  
 ischemia, cardiac arrhythmia, essential and pulmonary hypertension, renal disease, acute and  
 20 chronic renal failure, end stage renal disease, peripheral vascular disease, male erectile  
 dysfunction, diabetic retinopathy, intermittent claudication/ischemic limb disease,  
 ischemic/hemorrhagic stroke, COPD, restenosis, asthma, neurogenic inflammation, migraine,  
 metabolic vasculopathies, bone/cartilage/joint diseases, arthritis and other inflammatory  
 diseases, fibrosis, pulmonary fibrosis, sepsis, atherosclerosis, dyslipidemia, addiction,  
 25 schizophrenia, cognitive disorders, Alzheimers disease, impulsivity, anxiety, stress,  
 depression, Parkinsons, movement disorders, sleep-wake cycle, inventive motivation, pain,  
 neuromuscular function, diabetes, gastric reflux, gastric motility disorders, ulcers and  
 genitourinary diseases.